索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]刘春雨 刘若鸿 杨 屹 孙红玉 汤礼军.微RNA作为胰腺疾病分子标志物的研究进展[J].国际消化病杂志,2018,03:153-157.
点击复制

微RNA作为胰腺疾病分子标志物的研究进展(PDF)

《国际消化病杂志》[ISSN:1673-534X/CN:31-1953/R]

期数:
2018年03期
页码:
153-157
栏目:
综述
出版日期:
2018-06-25

文章信息/Info

Title:
-
作者:
刘春雨 刘若鸿 杨 屹 孙红玉 汤礼军
610031 四川成都,西南交通大学医学院(刘春雨、杨屹、汤礼军); 610083 四川成都,成都军区总医院全军普通外科中心 四川省胰腺损伤与修复重点实验室(刘春雨、刘若鸿、杨屹、孙红玉、汤礼军)
Author(s):
-
关键词:
微RNA;  胰腺疾病;  标志物
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-534X.2018.03.001
文献标识码:
-
摘要:
微RNA(miRNA)是一类非编码小分子RNA,在转录后水平调节基因的表达,从而控制多种生物学过程。研究发现,miRNA不但在胰腺疾病中异常表达,而且在疾病发生、进展和转移等过程中发挥着重要作用。目前,越来越多的研究显示miRNA有望作为胰腺疾病诊断和预后评估的新的生物标志物。该文就miRNA在胰腺疾病中的研究进展作一综述。
Abstract:
-

参考文献/References

1 Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review[J]. EMBO Mol Med, 2012, 4(3): 143-159.
2 Jansson MD, Lund AH. MicroRNA and cancer[J]. Mol Oncol, 2012, 6(6): 590-610.
3 Bartel DP. MicroRNAs: target recognition and regulatory functions[J]. Cell, 2009, 136(2): 215-233.
4 Newman MA, Hammond SM. Emerging paradigms of regulated microRNA processing[J]. Genes Dev, 2010, 24(11): 1086-1092.
5 Morlando M, Ballarino M, Gromak N, et al. Primary microRNA transcripts are processed co-transcriptionally[J]. Nat Struct Mol Biol, 2008, 15(9): 902-909.
6 Yi R, Qin Y, Macara IG, et al. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs[J]. Genes Dev, 2003, 17(24): 3011-3016.
7 Lee Y, Ahn C, Han J, et al. The nuclear RNase Ⅲ Drosha initiates microRNA processing[J]. Nature, 2003, 425(6956): 415-419.
8 Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs[J]. Cell, 2009, 136(4): 642-655.
9 Jin Y, Chen Z, Liu X, et al. Evaluating the microRNA targeting sites by luciferase reporter gene assay[J]. Methods Mol Biol, 2013, 936: 117-127.
10 Saetrom P, Heale BS, Snove O Jr, et al. Distance constraints between microRNA target sites dictate efficacy and cooperativity[J]. Nucleic Acids Res, 2007, 35(7): 2333-2342.
11 Bhardwaj A, Singh S, Singh AP. MicroRNA-based cancer therapeutics: big hope from small RNAs[J]. Mol Cell Pharmacol, 2010, 2(5): 213-219.
12 Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review[J]. EMBO Mol Med, 2012, 4(3): 143-159.
13 Backes C, Meese E, Keller A. Specific miRNA disease biomarkers in blood, serum and plasma: challenges and prospects[J]. Mol Diagn Ther, 2016, 20(6): 509-518.
14 Park NJ, Zhou H, Elashoff D, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection[J]. Clin Cancer Res, 2009, 15(17): 5473-5477.
15 Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer[J]. Urol Oncol, 2010, 28(6): 655-661.
16 Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A, 2008, 105(30): 10513-10518.
17 Devaux Y, Stammet P, Friberg H, et al. MicroRNAs: new biomarkers and therapeutic targets after cardiac arrest?[J]. Crit Care, 2015, 19(1): 54.
18 Budhu A, Ji J, Wang XW. The clinical potential of microRNAs[J]. J Hematol Oncol, 2010, 3(1): 37.
19 Endo K, Weng H, Kito N, et al. MiR-216a and miR-216b as markers for acute phased pancreatic injury[J]. Biomed Res, 2013, 34(4): 179-188.
20 Wang J, Huang W, Thibault S, et al. Evaluation of miR-216a and miR-217 as potential biomarkers of acute exocrine pancreatic toxicity in rats[J]. Toxicol Pathol, 2017, 45(2): 321-334.
21 Smith A, Calley J, Mathur S, et al. The rat microRNA body atlas; evaluation of the microRNA content of rat organs through deep sequencing and characterization of pancreas enriched miRNAs as biomarkers of pancreatic toxicity in the rat and dog[J]. BMC Genomics, 2016, 17(1): 694.
22 Blenkiron C, Askelund KJ, Shanbhag ST, et al. MicroRNAs in mesenteric lymph and plasma during acute pancreatitis[J]. Ann Surg, 2014, 260(2): 341-347.
23 An F, Zhan Q, Xia M, et al. From moderately severe to severe hypertriglyceridemia induced acute pancreatitis: circulating miRNAs play role as potential biomarkers[J]. PLoS One, 2014, 9(11): e111058.
24 Kus'nierz-Cabala B, Nowak E, Sporek M, et al. Serum levels of unique miR-551-5p and endothelial-specific miR-126a-5p allow discrimination of patients in the early phase of acute pancreatitis[J]. Pancreatology, 2015, 15(4): 344-351.
25 Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis[J]. JAMA, 2007, 297(17): 1901-1908.
26 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29.
27 Ganepola GA, Rutledge JR, Suman P, et al. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer[J]. World J Gastrointest Oncol, 2014, 6(1): 22-33.
28 Frampton AE, Giovannetti E, Jamieson NB, et al. A microRNA meta-signature for pancreatic ductal adenocarcinoma[J]. Expert Rev Mol Diagn, 2014, 14(3): 267-271.
29 Kawaguchi T, Komatsu S, Ichikawa D, et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer[J]. Br J Cancer, 2013, 108(2): 361-369.
30 Liu J, Gao J, Du Y, et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer[J]. Int J Cancer, 2012, 131(3): 683-691.
31 Papaconstantinou IG, Manta A, Gazouli M, et al. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance[J]. Pancreas, 2013, 42(1): 67-71.
32 Schultz NA, Andersen KK, Roslind A, et al. Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index[J]. World J Surg, 2012, 36(11):2699-2707.
33 Ohuchida K, Mizumoto K, Kayashima T, et al. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer[J]. Ann Surg Oncol, 2011, 18(8): 2381-2387.
34 Ikenaga N, Ohuchida K, Mizumoto K, et al. MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma[J]. Ann Surg Oncol, 2010, 17(12): 3120-3128.
35 Habbe N, Koorstra JB, Mendell JT, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia[J]. Cancer Biol Ther, 2009, 8(4): 340-346.
36 Li A, Yu J, Kim H, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls[J]. Clin Cancer Res, 2013, 19(13): 3600-3610.
37 Permuthwey J, Chen DT, Fulp WJ, et al. Plasma microRNAs as novel biomarkers for patients with intraductal papillary mucinous neoplasms of the pancreas[J]. Cancer Prev Res(Phila), 2015, 8(9): 826-834.
38 Olson P, Lu J, Zhang H, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer[J]. Genes Dev, 2009, 23(18): 2152-2165.
39 Zhou HQ, Chen QC, Qiu ZT, et al. Integrative microRNA-mRNA and protein-protein interaction analysis in pancreatic neuroendocrine tumors[J]. Eur Rev Med Pharmacol Sci, 2016, 20(13): 2842-2852.
40 Kang BK, Hwang IK, Lee YS, et al. MicroRNA-27b as a prognostic marker in pancreatic neuroendocrine tumor[J]. J Clin Oncol, 2014, 32(3 Suppl): 251.
41 Nielsen LB, Wang C, Sørensen K, et al. Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression[J]. Exp Diabetes Res, 2012, 2012: 896362.
42 Marchand L, Jalabert A, Meugnier E, et al. miRNA-375 a sensor of glucotoxicity is altered in the serum of children with newly diagnosed type 1 diabetes[J]. J Diabetes Res, 2016, 2016: 1869082.
43 Zhang T, Li L, Shang Q, et al. Circulating miR-126 is a potential biomarker to predict the onset of type 2 diabetes mellitus in susceptible individuals[J]. Biochem Biophys Res Commun, 2015, 463(1-2): 60-63.
44 Al-Kafaji G, Al-Mahroos G, Al-Muhtaresh HA, et al. Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker[J]. Exp Ther Med, 2016, 12(2): 815-822.
45 Barutta F, Bruno G, Matullo G, et al. MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB Prospective Complications Study[J]. Acta Diabetol, 2017, 54(2): 133-139.

备注/Memo

备注/Memo:
基金项目:国家临床重点专科建设项目(41732113); 国家自然科学基金(81772001); 四川省科技厅应用基础研究重点项目(2018JY0041)
作者单位:610031 四川成都,西南交通大学医学院(刘春雨、杨屹、汤礼军); 610083 四川成都,成都军区总医院全军普通外科中心 四川省胰腺损伤与修复重点实验室(刘春雨、刘若鸿、杨屹、孙红玉、汤礼军)
通信作者:汤礼军,Email: tanglj2016@163.com; 孙红玉,Email: shongyu2008@163.
更新日期/Last Update: 2018-06-25